Cipla Ltd.


  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
May 26, 2017
Prev close: 491.6
May 26, 2017
Market cap:
Market cap(USD):
Shares: 804.54M

Currency in INR

Company profile

Market(Ticker): BOM(500087)
Health Technology
Pharmaceuticals: Other
Full time employees: 24,093

Business summary

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. Its products portfolio include prescription drugs, animal healthcare products, bulk drugs, OTC products, agrochemicals and technology. The company offers technology services such as consulting, project appraisal, engineering, plant supply, commissioning, training, know-how transfer and quality control. It operates through the following geographical segments: India, USA, South Africa, and Rest of the World. Cipla was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

Company background

Cipla is a major Indian generic drugmaker, competing for second place in the industry in India in terms of the size of its business. It has been doing business in 170 countries and has over 30 production bases. It is a long-established company compared with other Indian leading generic drugmakers. The predecessor of Cipla was founded by K. A. Hamied in 1935, long before India's independence in 1947. It is said that Mahatma Gandhi visited Cipla and asked Hamied to supply medicines that were desperately needed in India at the time. During World War II, Hamied crisscrossed the country to supply medicines that were in short supply due to stagnant imports.

As a trailblazer in India's pharmaceutical industry, Cipla has been busily expanding its business in Africa and other emerging economies. In particular, it is well-known for its low-cost HIV drug. In 2013, it turned a South African company it did business with into a wholly owned subsidiary.

K. A. Hamied's son Yusuf, who earned a doctorate in organic chemistry from the University of Cambridge, took over the company in 1972 and has been serving as the chairman. The founding family owns nearly 40% of the shares in the company.

In the news

Financial highlights

Mar 2016

  • Local currency
  • US Dollar
Revenue 134,356.2M
Gross profit 47,926.2M
Operating income 17,671.2M
Income before tax 20,069.6M
Net income 15,059.2M
EBITDA 23,087.7M
Diluted EPS 18.7
Dividends per share 2
Total assets 226,867.7M
Total liabilities 105,597.2M
Total equity 118,574.2M
Operating cash flow 16,416.3M

Currency in INR

Revenue 2,052.15M
Gross profit 732.02M
Operating income 269.90M
Income before tax 306.54M
Net income 230.01M
EBITDA 352.64M
Diluted EPS 0.28
Dividends per share 0.03
Total assets 3,425.83M
Total liabilities 1,594.58M
Total equity 1,790.54M
Operating cash flow 250.74M

Currency in USD

Valuation measures

Mar 2016

PER 27.31
ROA 7.51%
ROE 13.29%
Operating margin 13.15%
Profit margin 11.20%

Key executive

  • Group Chief Executive Officer & Managing Director: Umang Vohra
  • Global Chief Financial Officer: Kedar Upadhye
  • Secretary & Compliance Officer: Mital Sanghvi
  • Executive Vice Chairman: Samina Vaziralli
  • Head-Investor Relations: Alpesh Dalal

Share holders

  • AHMED SOPHIE(5.7%)
  • Life Insurance Corp. of India(5.6%)
  • ICICI Prudential Asset Management Co. Ltd.(5.1%)
  • First State Investment Management (UK) Ltd.(3.0%)
  • HDFC Asset Management Co. Ltd.(1.6%)
  • Norges Bank Investment Management(1.6%)
  • The Vanguard Group, Inc.(1.3%)


  • Website:
  • Address: Mumbai Central, Mumbai, 400 008, India
  • Phone: +91.22.23082891

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.